Paroxysmal Atrial Fibrillation
Conditions
Brief summary
Enrolled subjects will be treated with the Synaptic Cryoablation System. Treatment will include cryoablation of the pulmonary veins to achieve PVI. All subjects will be followed for twelve (12) months after completion of the index ablation procedure.
Detailed description
A multi-center, open-label, prospective, single-arm, pre-market clinical study. Enrolled subjects will be treated with the Synaptic Cryoablation System. Treatment will include cryoablation of the pulmonary veins to achieve PVI. All subjects will be followed for twelve (12) months after completion of the index ablation procedure. Data will be collected at enrollment, procedure, discharge, 1, 3, 6 and 12- months to assess the safety and effectiveness of the System. Testing for recurrence of atrial fibrillation will include a 12-lead ECG at 1, 3, 6 and 12-months post-ablation, weekly event recorder transmissions (TTM) after the 3-month follow-up visit through the 12-month follow up, and a 24-h continuous Holter ECG recording at 6 and 12-months post ablation. Symptom triggered rhythm monitoring will be used throughout the effectiveness post-ablation period.
Interventions
DEVICESynaptic Cryoablation System
The Synaptic Cryo Balloon must be used to isolate all targeted pulmonary veins. Entrance block will be confirmed in all targeted pulmonary veins (PVs) after a 20-minute waiting period or provocative testing with adenosine or isoproterenol. Any additional ablation in the LA beside PV isolation is not allowed in this protocol. Additional ablation of the cavo-tricuspid isthmus (CTI) with a conventional market-approved RF catheter is allowed only in case a typical atrial flutter is documented in prior patient history or occurs during the case (either spontaneously or inducible).
Sponsors
Synaptic Medical Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of symptomatic Paroxysmal Atrial Fibrillation (PAF), defined as atrial fibrillation that terminates spontaneously or with intervention (either through procedure or drug therapy) within seven (7) days of onset. Minimum documentation includes the following: 1. A physician's note indicating recurrent atrial fibrillation (AF) which includes at least two (2) symptomatic AF episodes within six (6) months prior to enrollment; AND 2. One electrocardiographically (from any form of rhythm monitoring, including consumer devices) documented AF episode within 12 months prior to enrollment. * Refractory or intolerant to at least one (1) Class I or III anti-arrhythmic medication or contraindicated to any class I or III medication. * Suitable candidate for catheter ablation. * Adults aged 18 - 80 years. * Willing and able to comply with all baseline and follow-up evaluations for the full length of the study. * Willing and able to provide informed consent.
Exclusion criteria
* Diagnosis of persistent AF, i.e., continuous AF lasting longer than seven (7) days from onset * In the opinion of the Investigator, any known contraindication to an atrial ablation or anticoagulation. Including but not limited to the identification of any atrial thrombus or evidence of sepsis * History of previous left atrial ablation or surgical treatment for AF/AFL/AT * Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiac cause * Body Mass Index (BMI) ≥ 40 * Structural heart disease or implanted devices as described below: 1. Left ventricular ejection fraction (LVEF) \< 40% based on most recent transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE) performed ≤ 180 days prior to enrollment 2. Left atrial diameter \> 5.5 cm or left atrial volume \> 50 ml/m2 indexed based on most recent TTE or TEE performed ≤ 180 days prior to enrollment 3. Implanted pacemaker, ICD, CRT device within 90 days prior to enrollment 4. Previous cardiac surgery, ventriculotomy, or atriotomy (excluding atriotomy for CABG) 5. Previous cardiac valvular surgical or percutaneous procedure, or prosthetic valve, including mitral valve clips 6. Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occluder 7. Presence of a left atrial appendage occlusion device 8. Presence of any pulmonary vein stents 9. Coronary artery bypass graft (CABG), PTCA, PCI, or coronary stent procedures within 90 days prior to enrollment 10. Unstable angina or ongoing myocardial ischemia 11. ST-Elevation Myocardial Infarction (STEMI) within 90 days prior to enrollment 12. Moderate or Severe Mitral Insufficiency or Mitral Stenosis, severity based on the most recent TTE or TEE performed ≤ 180 days prior to enrollment 13. Evidence of left atrial thrombus * History of cryoglobulinemia * Significant untreated restrictive or obstructive pulmonary disease or chronic respiratory condition * Renal failure requiring dialysis * History of blood clotting or bleeding disease * History of documented cerebral infarct, TIA or systemic embolism,excluding post-operative deep vein thrombosis (DVT) ≤ 180 days prior to enrollment * Active systemic infection * Pregnant or lactating (current or anticipated during the study) * Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study * Any other condition that, in the judgment of the Investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes, but not limited to, vulnerable patient population, mental illness, Gastroesophageal Reflux Disease (GERD), addictive disease, terminal illness with a life expectancy of less than two (2) years, or extensive travel away from the research center)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| safety - proportion of subjects who experienced device/procedure related Major Adverse Events (MAEs) | 6 months | The primary endpoint for safety is an analysis of the proportion of subjects who experienced device/procedure related Major Adverse Events (MAEs) that occur during the procedure or through the 6-month follow-up of the study. MAEs include any of the major complications as defined in the 2017 HRS expert consensus statement |
| Effectiveness | 12 months | The primary effectiveness endpoint is freedom from documented recurrence of AF, atrial tachycardia (AT), or atrial flutter (AFL) based on electrocardiographic data through 12-month follow-up and excluding a 90- day blanking period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety - Change from baseline NIH Stroke Scale post-ablation | Day 1 | Change from baseline NIH Stroke Scale post-ablation |
| Effectiveness - Rate of acute procedural success, defined as confirmation of entrance block in all targeted pulmonary veins | Day 0 | Rate of acute procedural success, defined as confirmation of entrance block in all targeted pulmonary veins |
| Effectiveness - Rate of pulmonary vein isolation on a per-vein basis | Day 0 | • Rate of pulmonary vein isolation on a per-vein basis |
| Effectiveness - Use of antiarrhythmic drugs (AADs) during the effectiveness evaluation period | 12 months | Use of antiarrhythmic drugs (AADs) during the effectiveness evaluation period |
| Effectiveness - Freedom from documented symptomatic AF or new onset of AFL/AT through 12-month follow-up and excluding the 90- day blanking period | 12 months | Freedom from documented symptomatic AF or new onset of AFL/AT through 12-month follow-up and excluding the 90- day blanking period |
| Effectiveness - Freedom from documented symptomatic AF or new onset of AFL/AT off antiarrhythmic drug therapy through 12-month follow-up and excluding the 90-day blanking period | 12 months | Freedom from documented symptomatic AF or new onset of AFL/AT off antiarrhythmic drug therapy through 12-month follow-up and excluding the 90-day blanking period |
| Effectiveness - Failure-free rate as defined in primary effectiveness endpoint at 6 months post procedure | 6 months | Failure-free rate as defined in primary effectiveness endpoint at 6 months post procedure |
| Safety - Incidence of late onset (>7 days) of SAEs | 12 months | Incidence of late onset (\>7 days) of SAEs |
| Performance - Procedure time, defined as the time elapsed from first venous access to last sheath removal | Day 0 | Procedure time, defined as the time elapsed from first venous access to last sheath removal |
| Performance - Duration of LA dwell time, defined as time from the Cryo Balloon Catheter exiting the sheath in the LA to time of final PVI | Day 0 | Duration of LA dwell time, defined as time from the Cryo Balloon Catheter exiting the sheath in the LA to time of final PVI |
| Performance - Total cryoablation time for index procedure | Day 0 | Total cryoablation time for index procedure |
| Performance - Total fluoroscopy time for index procedure | Day 0 | Total fluoroscopy time for index procedure |
| Performance - Treatment time, defined as the time from the start of the first ablation delivery to the end of the last ablation delivery | Day 0 | Treatment time, defined as the time from the start of the first ablation delivery to the end of the last ablation delivery |
| Performance -Changes in the quality-of-life measures (AFEQT) between baseline and 12-month follow-up | 12 months | Changes in the quality-of-life measures (AFEQT) between baseline and 12-month follow-up |
| Performance - Single procedure success defined as freedom from primary effectiveness failure without a repeat procedure | 12 months | Single procedure success defined as freedom from primary effectiveness failure without a repeat procedure |
| Safety - Incidence of early onset (within 7 days of the index ablation procedure) of serious adverse events (SAEs) | 7 days | Incidence of early onset (within 7 days of the index ablation procedure) of serious adverse events (SAEs) |
Countries
United States
Outcome results
None listed